Mapping of T cell recognition to the SARS-CoV-2 provides new knowledge for vaccine design and therapeutic interventions

Viruses Genes and genomes Health technology Health and diseases

In an accelerated research project to support global efforts in understanding and mitigating the COVID-19 pandemic, researchers from DTU Health Tech and Herlev University Hospital have analyzed the complete SARS-CoV-2 viral genome and identified the viral regions that are main targets for T cell mediated immune response in COVID-19 patients.

These findings are of immense importance in assessing the immune response in COVID-19 disease, to understand the mechanisms that influence disease severity and to optimize future effective vaccine designs.

T cells are important for effective viral clearance and long-term disease protection by recognizing small fragments (antigens) of viral proteins. In SARS-CoV-2 infection, early T cell activation has been reported in several studies. Thus, a detailed evaluation of T cell immunity and its clinical implication in COVID-19 disease is necessary to know the full spectrum of SARS-CoV-2-reactive T cells and their immunogenic properties.

A research team headed by Professor Sine Reker Hadrup, DTU Health Tech, now show that SARS-COV-2 infections generate a broad and strong T cell response against several viral antigens in COVID-19 disease.

Assistant Professor Sunil Kumar Saini explains: “We have found that a few viral fragments dominated the T cell activation in the majority of patients, showing immunodominance of specific viral proteins. This is based on our analysis of more than 3000 viral fragments (peptides) for T cell recognition in COVID-19 patients. Importantly, we identified that strong T cell expansion and activation is associated with severe COVID-19 disease.”

Furthermore, this study provides a detailed analysis of pre-existing T cells in healthy individuals that recognize SARS-CoV-2 antigens. These features of the T cell mediated immunity can be leveraged into therapeutic intervention and vaccine design.

These results have been published in Science Immunology.

(Photo by Jesper Scheel)